English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Pancreatic intraductal papillary mucinous neoplasms (IPMN) are one of the precursors lesions of pancreatic adenocarcinoma. They have only been individualized as a specific disease in the mid 80’s and were first recognized by the World Health Organization in 1996. Since then, significant progress has been made in the diagnosis, understanding of the natural history and management of this frequent pancreatic neoplasm. Nevertheless, there are still numerous unanswered questions that make difficult patients management.

Pancreatic Intraductal Papillary Mucinous Neoplasms.... Still Unanswered Questions!